Dustin Armstrong, PhD

Chief Scientific Officer, Valerion

Dr. Armstrong founded Valerion, formerly 4s3 Bioscience, in 2007 and as Chief Scientific Officer he has lead the company’s scientific efforts for program development; including, target identification, product generation, and feasibility studies. Dr. Armstrong manages development programs in the area of orphan genetic muscle disease as well as oncology applications and development of the Valerion platform delivery technology. As a primary investigator, Dr. Armstrong has obtained NIH support, matching MDA Venture Philanthropy funding, and a competitive accelerator loan from the State of Massachusetts Life Science Center to further Valerion programs. With over 10+ years of industry experience, Dr. Armstrong is the inventor of many company sponsored intellectual property filings including several issued U.S. Patents. Prior to founding Valerion, Dr. Armstrong worked for Novartis at the company’s Global Research & Development Center in Cambridge, MA. In the Models of Disease Group, Dr. Armstrong’s research focused on epigenetic control and pharmacological activation of endogenous muscle stem cells. Dr. Armstrong is a graduate of Alma College and completed his PhD work at the University of Illinois at Chicago.